FLKS Shrinks, SCPH Awaits FDA Decision In June, CLSD Looking Ahead To PEACHTREE

The following are some of today’s top losers in the pharma/biotech sector.

1. Flex Pharma Inc. (FLKS)

Lost 12.06% to close Tuesday’s (Dec.5) trading at $3.79.

News: No news

Clinical trials & Near-term catalysts:

— A phase II placebo-controlled, cross-over study testing FLX-787 in patients who suffer from spasticity, cramps and spasms as a consequence of multiple sclerosis is ongoing in Australia. Top-line results from this study are expected at the end of the first quarter of next year.
— A phase II trial of FLX-787 in patients with Charcot-Marie-Tooth who suffer from cramps in the U.S., dubbed COMMIT, was initiated as recently as October of this year. Top line results from this study are expected in the middle of 2018.

2. Ra Pharmaceuticals Inc. (RARX)

Lost 10.65% to close Tuesday’s trading at $7.97. This is the second straight day of loss for the stock.

Recent event:

— On December 4, 2017, the Company reported positive interim results from its phase II study of RA101495 SC in Paroxysmal Nocturnal Hemoglobinuria, or PNH. However, investors seem to be not impressed with the results.

3. scPharmaceuticals Inc. (SCPH)

Lost 9.88% to close Tuesday’s trading at $15.60.

Recent event:

— The Company went public on the Nasdaq Global Select Market on November 17, 2017, offering its shares at a price of $14 each.

Near-term catalysts:

— The Company’s 505(b)(2) New Drug Application for Furoscix for treatment of worsening, or decompensated, heart failure outside of the inpatient setting is under FDA review – with a decision expected on June 23, 2018.

4. Clearside BioMedical Inc. (CLSD)

Lost 9.85% to close Tuesday’s trading at $6.17.

News: No news

Clinical trials & Near-term catalysts:

— A pivotal phase III trial of suprachoroidal CLS-TA in patients with macular edema associated with non-infectious uveitis, dubbed PEACHTREE, is underway – with preliminary results expected in the first quarter of 2018.
— A phase III clinical trial of suprachoroidal CLS-TA used in combination with intravitreally administered EYLEA in patients with Retinal Vein Occlusion, dubbed SAPPHIRE, is ongoing. Preliminary data from this trial are anticipated in the first quarter of 2019.
— Initiate a second phase III clinical trial of suprachoroidal CLS-TA in combination with an anti-VEGF agent for the treatment of patients with Retinal Vein Occlusion, known as TOPAZ, in the first quarter of 2018.
— A phase II clinical trial of suprachoroidal CLS-TA used in combination with intravitreal Eylea in patients with…

Read the full article from the Source…

Leave a Reply

Your email address will not be published. Required fields are marked *